Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma (Q37921284)

25 August 2017

1 reference

title

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma (English)

1 reference

25 August 2017

0 references

Gillian M Keating

1 reference

25 August 2017

language of work or name

1 reference

1 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

1623-1647

1 reference

Peripheral blood stem cell mobilization tactics

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Advances in mobilization for the optimization of autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Improving stem cell mobilization strategies: future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian exp

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Controversies in the treatment of lymphoma with autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Relevance and Clinical Implications of Tumor Cell Mobilization in the Autologous Transplant Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Outcome, toxicity profile and cost analysis of autologous stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

The Feasibility of Plerixafor as a Second-line Stem Cell Mobilizing Agent in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206040-000000000-00000

The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation

21 January 2018

1 reference

12 December 2020

Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience

1 reference

12 December 2020

Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation

1 reference

12 December 2020

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

1 reference

12 December 2020

Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy

1 reference

12 December 2020

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma

1 reference

12 December 2020

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

12 December 2020

Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone

1 reference

12 December 2020

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

1 reference

12 December 2020

Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA

1 reference

12 December 2020

Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients

1 reference

12 December 2020

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

1 reference

12 December 2020

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

1 reference

12 December 2020

A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor

1 reference

12 December 2020

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.

1 reference

12 December 2020

An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy

1 reference

12 December 2020

Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization

1 reference

12 December 2020

Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells

1 reference

12 December 2020

Plerixafor ‘just in time’ for stem cell mobilization in a normal donor

1 reference

12 December 2020

Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements afte

1 reference

12 December 2020

Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: A simple method using day 1 CD34+ cell yield

1 reference

12 December 2020

Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients

1 reference

12 December 2020

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

12 December 2020

Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics

1 reference

12 December 2020

Use of Plerixafor with Granulocyte Colony-Stimulating Factor for Stem Cell Mobilization in a Pediatric Patient

1 reference

12 December 2020

High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation

1 reference

12 December 2020

Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation for medulloblastoma in a young child

1 reference

12 December 2020

10.2165/11206040-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1005150760

0 references

1 reference